β All ComparisonsKRXNYSE/NASDAQ
Healthcare
Celltrion
068270VS
Eli Lilly & Co.
LLYBiosimilars vs novel drugs - Korea vs US bio blue chip investment comparison
Celltrion
068270β©190,000
β² 3,000 (+1.60%)
Korea's largest biosimilar company. Global sales of blockbuster biosimilars including Remsima and Truxima.
Eli Lilly & Co.
LLY$820.50
β² 15.3 (+1.90%)
Explosive growth with GLP-1 obesity/diabetes drugs Mounjaro/Zepbound. Global top 10 pharma by market cap.
Key Metrics Comparison
Celltrion
Key Metrics Comparison
Eli Lilly & Co.
β©190,000
Price
$820.50
+1.60%
Change
+1.90%
22.7
P/E Ratio
68.4
β©40.8μ‘°
Market Cap
$780B
β©230,000
52W High
$950.00
β©165,000
52W Low
$580.00
1.3M
Volume
5.2M
About the Companies
Celltrion
Korea's largest biosimilar company. Global sales of blockbuster biosimilars including Remsima and Truxima.
Eli Lilly & Co.
Explosive growth with GLP-1 obesity/diabetes drugs Mounjaro/Zepbound. Global top 10 pharma by market cap.
β» All data is for reference only and not real-time. Investment decisions are the sole responsibility of the investor. This comparison is not investment advice.
Other Comparisons
Celltrion vs Samsung Biologics
Healthcare
Eli Lilly & Co. vs UnitedHealth GroupHealthcare
Samsung Biologics vs UnitedHealth GroupHealthcare
Samsung Electronics vs Celltrionblue-chip
SK Hynix vs Celltrionblue-chip
NAVER vs Celltrionblue-chip
Kakao vs Celltrionblue-chip
Hyundai Motor vs Celltrionblue-chip
LG Energy Solution vs Celltrionblue-chip